Fisher Scientific said this week that it agreed to acquire Dharmacon for $80 million in cash, putting to rest rumors circulating throughout the industry that the privately held RNA reagent provider was on the block.

Fisher said that acquiring Dharmacon — which generated about $17 million in revenues last year — will help expand the company’s presence in the life sciences market, and is expected to help boost sales of higher-margin, proprietary products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.